Immune responses following COVID-19 infection in multiple sclerosis patients using immunomodulatory therapy

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2), has quickly become a global pandemic. Most multiple sclerosis (MS) patients use disease-modifying treatments (DMTs), such as immunomodulators or immunosuppressants. By targeting differen...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilge, Nuray, Kesmez Can, Fatma, Yevgi, Recep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638386/
https://www.ncbi.nlm.nih.gov/pubmed/36331727
http://dx.doi.org/10.1007/s13760-022-02125-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638386/
https://www.ncbi.nlm.nih.gov/pubmed/36331727
http://dx.doi.org/10.1007/s13760-022-02125-6

Ejemplares similares